Results 111 to 120 of about 8,113 (209)

Severe digital ischemia due to systemic sclerosis successfully treated with bosentan: case report [PDF]

, 2007
Cesar José Guimarães Soares, Bóris Afonso Cruz   +1 more
openalex   +1 more source

Bosentan

Drugs in R & D, 1999
openaire   +2 more sources

Severe COVID-19 Pneumonia, Opportunistic Candida krusei Infection, and Acute Respiratory Distress Syndrome with Pulmonary Arterial Hypertension Treated with Bosentan: A Case Report. [PDF]

Am J Case Rep
Briones-Claudett KH, Briones-Zamora KH, Benites Solis JG, Huilcapi Borja DI, Arteaga Ocaña KN, Touriz Bonifaz MA, Barberan-Torres P, Grunauer M.   +7 more
europepmc   +1 more source

A randomised, controlled trial of bosentan in severe COPD [PDF]

, 2008
Daiana Stolz, Helmut Rasch, A. Linka, Marcello Di Valentino, Andrea H. Meyer, Martin Brutsche, Michael Tamm   +6 more
openalex   +1 more source

Meta-analysis of targeted drugs for pulmonary hypertension to improve exercise tolerance and associated factors in eisenmenger syndrome. [PDF]

J Cardiothorac Surg
Yuan Z, Wang Y, Wang J, Lai Y, Dan X, Wang J.   +5 more
europepmc   +1 more source

Duration of right ventricular contraction predicts the efficacy of bosentan treatment in patients with pulmonary hypertension [PDF]

, 2008
M. G. J. Duffels, Maxim Hardziyenka, Sulaiman Surie, Rianne H.A.C.M. de Bruin‐Bon, Elke S. Hoendermis, Arie P.J. van Dijk, Berto J. Bouma, Han L. Tan, Rolf M.F. Berger, Paul Bresser, Barbara J.M. Mulder   +10 more
openalex   +1 more source

Endothelial dysfunction in single ventricle physiology and the Fontan circulation - What lies ahead. [PDF]

Int J Cardiol Congenit Heart Dis
Agarwal R, Coats LE, Zaidi AN.
europepmc   +1 more source

Bosentan in mild pulmonary hypertension – Authors' reply [PDF]

, 2008
Nazzareno Galiè, Gérald Simonneau
openalex   +1 more source

Pre-Formulation Studies of Lipid-Based Formulation Approach for a Poorly Water-Soluble Biopharmaceutics Classification System Class II Model Drug: Bosentan. [PDF]

Turk J Pharm Sci
Yılmaz Usta D, Teksin ZŞ.
europepmc   +1 more source

A systematic review of the current application status of decision-analytical models in the pharmacoeconomic evaluation of targeted therapies for pulmonary arterial hypertension. [PDF]

Cost Eff Resour Alloc
Dong W, Zhang Z, Wang X, Ma X, Chu M, Li Y, Xiang X, Peng C, Zhang R.   +8 more
europepmc   +1 more source